Notable concerns that warrant closer review
Royalties are a significant growth driver, fueled by the success of ENHANZE partner products, though price erosion on older products is a concern.. Product sales are growing, primarily from proprietary products, but are subject to the cyclical nature of partner demand for bulk rHuPH20 and partnered devices.. No material legal proceedings are currently ongoing that are expected to have a significant adverse effect on the company's financial statements.. Increase in royalties primarily driven by continued sales uptake of ENHANZE partner products launched since 2020, predominantly by VYVGART Hytrulo, DARZALEX SC, and Phesgo.